Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6190Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Craig Wallington-Gates | en |
| dc.date.accessioned | 2024-08-08T03:21:38Z | - |
| dc.date.available | 2024-08-08T03:21:38Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.citation | Blood, 2018 | en |
| dc.identifier.uri | https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6190 | - |
| dc.language.iso | en | en |
| dc.title | Phase 2 Trial of the Combination of Ixazomib, Thalidomide and Dexamethasone (ITD) in Relapsed/Refractory Myeloma: Planned Preliminary Analysis | en |
| dc.type | Article | en |
| dc.identifier.doi | 10.1182/blood-2018-99-118172 | - |
| dc.rights.holder | Craig Wallington-Gates | en |
| dc.identifier.journaltitle | Blood | - |
| dc.identifier.external | 96782364 | - |
| item.fulltext | No Fulltext | - |
| item.grantfulltext | none | - |
| item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
| item.cerifentitytype | Publications | - |
| item.languageiso639-1 | en | - |
| item.openairetype | Article | - |
| Appears in Sites: | Sunshine Coast HHS Publications | |
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.